New Research Programme Will Contribute to Improving the Legal Frameworks for Biomedical Innovation
Despite major scientific and technological advances, relatively few truly innovative drugs are approved today.
The aim of CeBIL is to analyse the most important legal obstacles to pharmaceutical innovation and thereby contribute to translating innovative biomedical research into new effective, affordable and easily accessible forms of treatment.
The goal of the Programme is to propose new frameworks for developing and regulating medicines. This will entail the generation and use of empirical data to enable rational and well-informed policies to be developed in the field and to facilitate the transition from research to innovation.
The head of CeBIL, Timo Minssen, says: “CeBIL is motivated by a genuine wish to contribute with interdisciplinary legal studies to strengthening Denmark’s and Europe’s innovation and competitiveness within the biomedical area, to create new jobs, and – very importantly – to meet the needs, values and expectations of citizens and patients.”
The Foundation has awarded DKK 35 million over 5 years for CeBIL, an international and strongly interdisciplinary research programme that includes collaboration with experts based in Denmark and elsewhere from academia, public authorities, patient organizations and industry.
Dagnia Looms, Head of Strategic Awards of the Novo Nordisk Foundation, says: “This research project will study the most significant legal barriers to pharmaceutical innovation and aims to generate data to support new legal frameworks for drug development incentives and regulations. This goal fits well with the Foundation’s ambition to promote innovation in biomedicine and biotechnology and build bridges between scientific discoveries and commercial applications.”
